Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 3
1968 6
1969 4
1970 6
1971 4
1972 4
1973 7
1974 8
1975 11
1976 7
1977 6
1978 15
1979 11
1980 7
1981 15
1982 13
1983 17
1984 16
1985 17
1986 15
1987 22
1988 18
1989 12
1990 24
1991 18
1992 25
1993 28
1994 35
1995 32
1996 33
1997 36
1998 46
1999 39
2000 31
2001 42
2002 34
2003 34
2004 47
2005 43
2006 69
2007 64
2008 71
2009 67
2010 68
2011 90
2012 90
2013 88
2014 86
2015 98
2016 75
2017 76
2018 88
2019 90
2020 93
2021 89
2022 65
2023 57
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

2,015 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.
Leary SES, Packer RJ, Li Y, Billups CA, Smith KS, Jaju A, Heier L, Burger P, Walsh K, Han Y, Embry L, Hadley J, Kumar R, Michalski J, Hwang E, Gajjar A, Pollack IF, Fouladi M, Northcott PA, Olson JM. Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321. doi: 10.1001/jamaoncol.2021.2224. JAMA Oncol. 2021. PMID: 34292305 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate therapy intensification with carboplatin as a radiosensitizer and isotretinoin as a proapoptotic agent in children with high-risk medulloblastoma in a randomized clinical trial and, with a correlative biology study, facilitate pl …
OBJECTIVE: To evaluate therapy intensification with carboplatin as a radiosensitizer and isotretinoin as a proapoptotic agent in children wi …
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R. Packer RJ, et al. J Clin Oncol. 2006 Sep 1;24(25):4202-8. doi: 10.1200/JCO.2006.06.4980. J Clin Oncol. 2006. PMID: 16943538 Clinical Trial.
PURPOSE: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. METHODS: Four hundred twenty-one patients b …
PURPOSE: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated wi …
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.
Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P Jr, Boop FA, Stewart CF, Harreld JH, Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA. Liu APY, et al. Cancer Cell. 2021 Nov 8;39(11):1519-1530.e4. doi: 10.1016/j.ccell.2021.09.012. Epub 2021 Oct 21. Cancer Cell. 2021. PMID: 34678152 Free PMC article.
Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the cerebellum, succumb to their disease. Conventional response monitoring by imaging and cerebrospinal fluid (CSF) cytology remains challenging, and a marker for measurable residual disease …
Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the cerebellum, succumb to their disease. Conventio …
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P Jr, Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Onar-Thomas A, Ellison DW, Northcott PA. Gajjar A, et al. J Clin Oncol. 2021 Mar 1;39(7):822-835. doi: 10.1200/JCO.20.01372. Epub 2021 Jan 6. J Clin Oncol. 2021. PMID: 33405951 Free PMC article. Clinical Trial.
PURPOSE: SJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma. ...CONCLUSION: These results est …
PURPOSE: SJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency …
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC. Schwalbe EC, et al. Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22. Lancet Oncol. 2017. PMID: 28545823 Free PMC article.
METHODS: In this retrospective cohort study, we assessed 428 primary medulloblastoma samples collected from UK Children's Cancer and Leukaemia Group (CCLG) treatment centres (UK), collaborating European institutions, and the UKCCSG-SIOP-PNET3 European clinical tr …
METHODS: In this retrospective cohort study, we assessed 428 primary medulloblastoma samples collected from UK Children's Cancer and …
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma.
Michalski JM, Janss AJ, Vezina LG, Smith KS, Billups CA, Burger PC, Embry LM, Cullen PL, Hardy KK, Pomeroy SL, Bass JK, Perkins SM, Merchant TE, Colte PD, Fitzgerald TJ, Booth TN, Cherlow JM, Muraszko KM, Hadley J, Kumar R, Han Y, Tarbell NJ, Fouladi M, Pollack IF, Packer RJ, Li Y, Gajjar A, Northcott PA. Michalski JM, et al. J Clin Oncol. 2021 Aug 20;39(24):2685-2697. doi: 10.1200/JCO.20.02730. Epub 2021 Jun 10. J Clin Oncol. 2021. PMID: 34110925 Free PMC article. Clinical Trial.
PURPOSE: Children with average-risk medulloblastoma (MB) experience survival rates of 80% at the expense of adverse consequences of treatment. ...Young children (3-7 years) were also randomly assigned to receive standard-dose CSI (SDCSI; 23.4 Gy) or low-dose CSI (LD …
PURPOSE: Children with average-risk medulloblastoma (MB) experience survival rates of 80% at the expense of adverse consequences of t …
Management of high-risk medulloblastoma.
Bouffet E. Bouffet E. Neurochirurgie. 2021 Feb;67(1):61-68. doi: 10.1016/j.neuchi.2019.05.007. Epub 2019 Jun 20. Neurochirurgie. 2021. PMID: 31229532 Review.
Medulloblastoma is the most common malignant brain tumors in children. Current management combines surgery, radiotherapy, and chemotherapy. Current treatment of medulloblastoma is based on a clinical risk-stratification system that takes into account age, ext …
Medulloblastoma is the most common malignant brain tumors in children. Current management combines surgery, radiotherapy, and chemoth …
How we treat medulloblastoma in adults.
Franceschi E, Seidel C, Sahm F, Pajtler KW, Hau P. Franceschi E, et al. ESMO Open. 2021 Aug;6(4):100173. doi: 10.1016/j.esmoop.2021.100173. Epub 2021 Jun 9. ESMO Open. 2021. PMID: 34118771 Free PMC article. Review.
Medulloblastoma is a rare tumour in postpubertal patients and adults that is potentially curable. ...Due to the good to intermediate prognosis, patients with medulloblastoma require structured long-term clinical follow-up including MRI of the brain, monitorin …
Medulloblastoma is a rare tumour in postpubertal patients and adults that is potentially curable. ...Due to the good to intermediate …
Radiotherapy Advances in Paediatric Medulloblastoma Treatment.
Padovani L, Horan G, Ajithkumar T. Padovani L, et al. Clin Oncol (R Coll Radiol). 2019 Mar;31(3):171-181. doi: 10.1016/j.clon.2019.01.001. Epub 2019 Jan 14. Clin Oncol (R Coll Radiol). 2019. PMID: 30655168 Review.
With modern multidisciplinary management, more than 80% of children with standard-risk medulloblastoma and up to 70% of children with high-risk medulloblastoma are long-term survivors. Current clinical trials are evaluating risk-adapted radiotherapy in standa …
With modern multidisciplinary management, more than 80% of children with standard-risk medulloblastoma and up to 70% of children with …
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I. Peyrl A, et al. JAMA Oncol. 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. JAMA Oncol. 2023. PMID: 37883081 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the response rate of pediatric patients with medulloblastoma recurrence using an antiangiogenic metronomic combinatorial approach (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial [MEMMAT]). ...TRIAL REGISTRA …
OBJECTIVE: To evaluate the response rate of pediatric patients with medulloblastoma recurrence using an antiangiogenic metronomic com …
2,015 results